London, ON – August 3, 2018 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announce it has entered into a Master Services Agreement (the “MSA”) with a Canadian biotech company for work on their international prospective clinical trial involving a novel cancer therapy guidance tool.
“We are excited to be collaborating with and working alongside a company that is looking to validate their tool for the management of primary breast cancer treatment. This particular area of oncology is a real passion for Stiris, having several breast cancer survivors on our team, we want to see earlier detection and of course improved treatment options and outcomes for all cancer patients.” Amanda Carrera, Vice President, Stiris Research Inc.
Breast Cancer is the most common cancer among Canadian women (excluding melanoma skin cancers). It is the 2nd leading cause of death from cancer in Canadian women. Breast cancer can also occur in men but is not common. An estimated 2.09 million cases of breast cancer were diagnosed in 2018 globally (www.cancer.ca).
About Stiris Research
Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.